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Abstract
Background: Diabetic cardiomyopathy, a diabetes-specific complication, refers to a disorder that eventually leads
to left ventricular hypertrophy in addition to diastolic and systolic dysfunction. In recent studies, hyperglycemia-
induced reactive oxygen species (ROS) in cardiomyocytes have been linked to diabetic cardiomyopathy. GATA
binding protein 4 (GATA-4) regulates the expression of many cardio-structural genes including cardiac troponin-I
(cTnI).
Methods: Streptozotocin-induced diabetic rats and H9c2 embryonic rat cardiomyocytes treated with a high
concentration of glucose (a D-glucose concentration of 30 mM was used and cells were cultured for 24 hr) were
used to examine the effect of hyperglycemia on GATA-4 accumulation in the nucleus. cTnI expression was found
to be linked to cardiac tonic dysfunction, and we evaluated the expression levels of cTnI and GATA-4 by Western
blot analysis.
Results: Cardiac output was lowered in STZ-induced diabetic rats. In addition, higher expressions of cardiac
troponin I (cTnI) and phosphorylated GATA-4 were identified in these rats by Western blotting. The changes were
reversed by treatment with insulin or phlorizin after correction of the blood sugar level. In H9c2 cells, ROS
production owing to the high glucose concentration increased the expression of cTnI and GATA-4
phosphorylation. However, hyperglycemia failed to increase the expression of cTnI when GATA-4 was silenced by
small interfering RNA (siRNA) in H9c2 cells. Otherwise, activation of ERK is known to be a signal for phosphorylation
of serine105 in GATA-4 to increase the DNA binding ability of this transcription factor. Moreover, GSK3b could
directly interact with GATA-4 to cause GATA-4 to be exported from the nucleus. GATA-4 nuclear translocation and
GSK3b ser9 phosphorylation were both elevated by a high glucose concentration in H9c2 cells. These changes
were reversed by tiron (ROS scavenger), PD98059 (MEK/ERK inhibitor), or siRNA of GATA-4. Cell contractility
measurement also indicated that the high glucose concentration decreased the contractility of H9c2 cells, and this
was reduced by siRNA of GATA-4.
Conclusions: Hyperglycemia can cause systolic dysfunction and a higher expression of cTnI in cardiomyocytes
through ROS, enhancing MEK/ERK-induced GATA-4 phosphorylation and accumulation in the cell nucleus.
Background
Diabetes ranks among the main risk factors for the devel-
opment of congestive heart failure (CHF) [1,2]. Many
patients with CHF and hyperglycemic symptoms have
accompanying abnormalities including obesity, dyslipide-
mia, and hypertension, which also lead to structural and
functional abnormalities of the heart in cardiac dysfunc-
tion and CHF [3-6]. The pathogenesis of left ventricular
diastolic dysfunction in diabetes and diabetic cardiomyo-
pathy has been extensively studied [7]. Intramyocardial
accumulation of triglycerides and extracellular deposition
of excess collagen and advanced glycation products trig-
ger glucolipotoxicity and activation of several signal path-
ways (insulin resistance, oxidative stress, renin-
angiotensin system, adipokines, and inflammation) in a
milieu of altered substrate metabolism [8,9].
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hyperglycemia. Reactive oxygen species (ROS) genera-
tion has been detected in cells exposed to a high glucose
concentration. Cell death such as apoptosis plays a criti-
cal role in cardiac pathogenesis. Thus, hyperglycemia
seems to be linked to apoptotic cell death in the myo-
cardium in vivo. Actually, hyperglycemia-induced myo-
cardial apoptosis is mediated by ROS produced owing
to the high glucose concentration [10-12].
It has been indicated that mutations in the cardiac
troponin I (cTnI) gene could lead to hypertrophic cardi-
omyopathy [13]. The proximal regions of the cardiac
TnI gene regulate its specific expression in the heart. A
proximal GATA-4-binding site in the cardiac TnI gene
is necessary for the transcriptional activation of this
gene in vitro, while other sites for GATA-4 DNA bind-
ing may contribute to the regulation of this gene [14].
Otherwise, it has been documented that MEK1-ERK1/2
signaling regulates the hypertrophic growth of cardio-
myocytes through the transcription factor GATA-4 by
direct phosphorylation of serine 105, which enhances
DNA binding and transcriptional activation [15,16]. The
ERK cascade plays an important role in the signaling
pathway leading to the development of myocardial
hypertrophy [17]. It is well-known that ROS can activate
extracellular signal-regulated kinases (ERK1/2) [18]. Pre-
vious studies have indicated that ERK phosphorylation
is important for the development of cardiac hypertrophy
induced by hyperglycemia [17,19-21]. Otherwise, GSK3b
h a sb e e nd e s c r i b e da sa ni n h i b i t o ro fh y p e r t r o p h i cs i g -
naling in the intact myocardium [22]. GSK3b -induced
nuclear export of GATA-4 may lower the nuclear accu-
mulation of GATA-4, while inhibition of GSK3b by LiCl
causes nuclear accumulation of GATA-4, suggesting
that GSK3b negatively regulates the nuclear expression
of GATA-4 [23].
Cardiac hypertrophy can be induced by hyperglycemia
[24,25] and MEK/ERK signaling could be triggered in a
high-glucose environment [26]. However, the role of
GATA-4 in hyperglycemia-induced cardiac hypertrophy
is still unknown. In the present study, we identified sig-
nals for hyperglycemia-induced cardiac hypertrophy,
especially for GATA-4 accumulation in the nucleus,
increasing cTnI over-expression.
Methods
Materials
Phlorizin was purchased from Fluka Chemie AG (Swit-
zerland). Insulin (Monotard
® H M )w a so b t a i n e df r o m
Novo Nordisk A/S (Bagsvaerd, Denmark). Tiron,
PD98059 and SB203580 were obtained from Sigma Che-
m i c a lC o .( S t .L o u i s ,M O ,U S A ) .O p t i - M E M
® IR e d u c e d
Serum Medium, Stealth™ Select RNAi (siRNA-GATA-
4), scrambled siRNA (siRNA-control), and Lipofectamine
2000™ were obtained from Invitrogen (Carlsbad, CA,
USA). Antibodies of phospho-GATA-4 (serine105)
(AB5245) and laminin (AB11575) were purchased from
Abcam (Cambridge, UK). Antibodies for cardiac TnI
(No. 4002), Phospho-GSK3b (Ser 9), GSK3b and Anti-
rabbit IgG, HRP-linked were purchased from Cell Signal-
ing Technology (Beverly, MA, USA). Antibodies to
G A T A - 4 ,H i s t o n eH 3a n dg o a ta n t i - r a b b i tI g G - H R P -
linked were obtained from Santa Cruz biotechnology,
Inc. (Santa Cruz, CA, USA). Anti-Actin Monoclonal
Antibody was purchased from Chemicon International,
Inc. (Billerica, MA, USA). Fluorescent conjugated sec-
ondary DyLight™ 549-conjugated AffiniPure Donkey
Anti-Goat IgG was purchased from Jackson ImmunoRe-
search Laboratories, Inc. (West Grove, PA, USA). 4’,6 -
diamidino-2-phenylindole (DAPI) was purchased from
Thermo Fisher Scientific, Inc. (Rockford, IL, USA).
Animal model
Eight-week-old male Wistar rats, weighing from 200 to
250 g, were obtained from the Animal Centre of
National Cheng Kung University Medical College. Dia-
betes was induced by intravenous injection of 60 mg/kg
streptozotocin as described previously[
1]. Animals were
considered hyperglycemic when their plasma glucose
concentration was 20 mmol/L or greater in addition to
polyuria and other hyperglycemic features. The levels of
plasma glucose were measured in blood samples col-
lected from the femoral vein of anesthetized rats (pento-
barbital, 30 mg/kg, i.p.) one hour before treatment.
Blood samples were centrifuged at 12,000 g for 3 min
then analyzed using glucose kit reagents (AppliedBio
assay kits; Hercules, CA, USA). The levels of plasma
glucose were then estimated by an auto-analyzer (Quik-
Lab, Ames, Miles, Inc., Elkhart, IN, USA), run in tripli-
cate. All studies were carried out 10 weeks after induc-
tion of diabetes.
Then, STZ-diabetic rats were anesthetized with an
intraperitoneal injection of urethane (1.4 g/kg) and can-
nulated in the right femoral artery with polyethylene
catheters (PE-50). Mean arterial pressure (MAP) and
heart rate (HR) were recorded using a polygraph (MP35,
BIOPAC, CA, USA). The trachea was intubated for arti-
ficial ventilation (Small Animal Ventilator Model 683,
Harvard Apparatus, Holliston, MA, USA) at 50 breaths/
min with a tidal volume of 8 mL/kg and a positive end
expiratory pressure of 5 cm H2O. After making an inci-
sion in the chest of the rat at the third intercostal space
to expose the heart, a small section (1 cm long) of the
ascending aorta was freed from the connective tissue. A
Transonic Flowprobe (2.5PSB923, Transonic System
Inc., Ithaca, NY, USA) was implanted around the root
of the ascending aorta and connected to a transonic
transit-time blood flowmeter (T403, Transonic System
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aortic blood flow; the difference in CO between STZ-
diabetic rats and normal rats was found.
Otherwise, 4 groups (n = 6 in each of groups) of age-
matched rats were used for investigation: group I, vehi-
cle-treated normal rats; group II, vehicle-treated STZ-
diabetic rats; group III, insulin-treated STZ-diabetic rats;
group IV, phlorizin- treated STZ-diabetic rats. The
STZ-diabetic rats of group III received intraperitoneal (i.
p.) injections of long-lasting human insulin (Monotards
HM) at 22.75 μg/kg every 8 hr, three times per day, as
d e s c r i b e dp r e v i o u s l y[ 2 7 ] .T h eS T Z - d i a b e t i cr a t so f
group IV received phlorizin by i.p. injection at a dose of
1 mg/kg every 8 hr according to the method described
previously [27]. Phlorizin was dissolved in a 20% solu-
tion of propylene glycol and diluted with saline to the
desired concentration for injection. Fluctuations in gly-
cemia were not observed in rats that received repeated
injections of insulin or phlorizin. Changes in protein
expression were determined from samples collected
after a 4-day treatment period. All animal procedures
were performed according to the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-
23, revised 1996), as well as the guidelines of the Animal
Welfare Act.
Cell culture and treatment
Primary cultures of cardiomyocytes from neonatal rats
were prepared with some modifications as described pre-
viously [1]. Briefly, heart tissue from a 1- to 2-day-old
W i s t a rr a tw a sc u ti n t o1 -t o2 - m mp i e c e sa n dp r e d i -
gested with trypsin to remove red blood cells. The heart
tissue was then digested with 0.25% trypsin and 0.05%
collagenase. The dissociated cells were placed in
uncoated 10-cm dishes and incubated at 37°C in a 5%
CO2 incubator for at least 1 hr to remove the nonmyocy-
tic cells. This procedure caused most of the fibroblasts to
attach to the dish, while most of the cardiomyocytes
remained unattached. The population of cells enriched in
cardiomyocytes was then collected and counted. The
cells were cultured in Dulbecco’s modified Eagle’sm e d -
ium (DMEM) purchased from GIBCO-BRL Life Technol-
o g i e s( G I B C OB R L ,G a i t h e r s b u r g ,M D ,U S A )w i t h1
mmol/L pyruvate, 10% fetal bovine serum (FBS), 100
units/mL penicillin, and 100 units/mL streptomycin. On
the second day after plating, the medium was replaced.
Three days after plating, the cells were exposed to hyper-
glycemic conditions, as described in detail later. Animal
handling and disposal were performed in accordance
with the NIH guidelines. Embryonic rat-heart-derived
H 9 c 2c e l l s( B C R CN o .6 0 0 9 6 )w e r eo b t a i n e df r o mt h e
Culture Collection and Research Center of the Food
Industry Institute (Hsin-Chiu City, Taiwan). The H9c2
cells were maintained in growth medium composed of
DMEM supplemented with 10% FBS. The H9c2 cells
were plated at a density of 6000 cells/cm
2 and allowed to
proliferate in growth medium. The medium was changed
every 48 hr. To induce differentiation of the H9c2 myo-
blasts into myotubes, the growth medium was replaced
by differentiation medium containing DMEM plus 2%
horse serum when the cells neared confluence[28].
Hyperglycemia-treated cardiomyocytes were generated
by treating the cells with 30 mmol/L glucose for 24 hr
[1]. In brief, cells were supplemented with 10% FBS and
antibiotics. After reaching approximately 60% conflu-
ence, serum-free cell media with various final concentra-
tions of D-glucose (5.5, 10, 20 or 30 mM) were
dispersed and cells were cultured for a further 24 hr
[25]. We used H9c2 cells exposed to 5.5 mM D-glucose
as a control. To rule out the effect of osmolarity, we
added 24.5 mM mannitol to the control cultures. High
glucose (HG)-treated cardiomyocytes were generated by
incubating cells with 30 mmol/L glucose for 24 hr [25].
The cells were treated with tiron (100 nmol/L),
PD98059 (20 μmol/L) and SB203580 (25 μmol/L) for 30
min before high-glucose treatment. After treating with a
high glucose concentration for 24 hr, the cells were
washed twice with PBS and removed by trypsinization.
Cells were then collected for Western blot analysis.
Measurement of superoxide generation
Superoxide production was analyzed by the lucigenin
method with modification [29]. H9c2 cells (10
6 cells)
were incubated in either control or HG medium for 24
hr in the presence or absence of the various treatments
described above. We also treated cells with rotenone, a
mitochondrial complex I inhibitor, as the positive con-
trol of superoxide generation [28,30]. H9c2 cells were
then trypsinized, collected by centrifugation and washed.
The resulting pellet was then re-suspended in 900 μLo f
Krebs buffer containing NaCl (130 mmol), KCl (5
mmol), MgCl2 (1 mmol), CaCl2 (1.5 mmol), K2HPO4 (1
mmol), and HEPES (20 mmol, pH 7.4, with 1 mg/mL
bovine serum albumin (BSA). To measure ROS produc-
tion, the suspensions were transferred into a measuring
chamber and assessed using a Chemiluminescence Ana-
lyzer (Tohoku Electronic Industrial Co., Ltd., Japan).
Suspensions were injected with 100 μL lucigenin (final
concentration, 4 × 10
-4 mmol/L) and photon emissions
were counted every 10 sec for up to 10 min.
DHE staining
For intracellular ROS detection, H9c2 cells (about 5,000)
were seeded onto 12-well cell culture plates. After 24 hr
of growth, cultures were placed in either control or HG
medium, treated as described above for 24 hr, and then
harvested. Also, cells treated with rotenone were used as
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H9c2 cells were fixed with 4% paraformaldehyde for 30
min. After fixation, the cells were washed three times
with PBS, and 5 μmol/L of dihydroethidium (DHE; Invi-
trogen) was added as a fluorescent indicator of ROS.
Images were collected using an Olympus IX70 fluores-
cence microscope fitted with an Olympus America cam-
era and MagnaFire 2.1 software.
Immunofluorescence cell staining
H9c2 cells (about 10,000) were seeded onto 6-well cell
culture plates. After 24 hr of growth, cultures were
placed in either control or HG medium, treated as
described above for 24 hr, and then harvested. The
H9c2 cells were fixed with 4% paraformaldehyde for 30
min. After fixation, the cells were washed three times
with phosphate-buffered saline (PBS). The tissue was
blocked with 5% BSA for 30 min at room temperature.
Primary antibodies diluted in 5% BSA (anti-phospho-
GATA-4 1:100) were incubated at 4°C overnight. There-
after, cells were washed in PBS and secondary antibodies
(DyLight™ 549-conjugated AffiniPure Donkey Anti-
Goat IgG 1:500) and were incubated for 30 min at room
temperature. Cells were then washed with PBS and
counterstained with 4’, 6-diamidino-2-phenylindole
(DAPI). Images were collected using an Olympus IX70
fluorescence microscope fitted with an Olympus Amer-
ica camera and MagnaFire 2.1 software.
Nuclear protein extraction
For nuclear protein extraction, the CNMCS Compart-
mental Protein Extraction Kit was purchased from Bio-
Chain Institute, Inc. CA, USA. In briefly, Cells were
collected using routine cell culture techniques. Count
cells and add ice cold lysis buffer at 2.0 ml per 20 mil-
lion cells. Mix the cells with buffer well and rotate the
mixture at 4°C for 20 min. Syringe with a needle gauged
between 26.5 and 30. Remove the needle tip by bending
the needle several times and only leave the needle base
on the syringe. Pass the cell mixture through needle
base 50-90 times to disrupt the cell membrane and
release the nuclei from the cells. The degree of cell
membrane disruption and nucleus release can be moni-
tored under microscope. Then spin the cells mixture at
15,000 g at 4°C for 20 min. The cytoplasmic proteins
are in the supernatant, take out and save in another
tube. Resuspend the pellet with ice cold wash buffer at
4.0 ml per 20 million cells; rotate at 4°C for 5 min. Spin
at 15,000 g at 4°C for 20 min. Drain the supernatant.
Add ice cold nuclear extraction buffer at 1.0 ml per 20
million cells to resuspend nuclear pellet, rotate at 4°C
for 20 min then spin at 15,000 g at 4°C for 20 min. The
nuclear proteins are in the supernatant, take out and
save for further detections.
Western blot analysis
Specific protein expression levels in rat hearts or H9c2
cells were determined by Western blot analysis. Protein
was extracted from tissue homogenates and cell lysates
using ice-cold radio-immuno-precipitation assay
(RIPA) buffer supplemented with phosphatase and pro-
tease inhibitors (50 mmol/L sodium vanadate, 0.5 mM
phenylmethylsulphonyl fluoride, 2 mg/mL aprotinin, and
0.5 mg/mL leupeptin). Proteins extracted using RIPA
buffer were separated by sodium dodecyl sulfate polya-
crylamide gel electrophoresis (SDS-PAGE), electrotrans-
f e r e da n di m m o b i l i z e do nan i trocellulose membrane.
The membrane was blocked with 5% non-fat milk in
PBS containing 0.1% Tween 20 (PBS-T) and incubated
for 2 hr. The membrane was then washed in PBS-T and
hybridized with primary antibodies, which were diluted
to a suitable concentration in PBS-T, for 16 hr. Incuba-
tion with secondary antibodies and detection of the anti-
gen-antibody complex were performed using an
Enzymatic Chemiluminescence (ECL) kit (Amersham
Biosciences, UK). Immunoblot densities were quantified
using a laser densitometer.
Small Interfering RNA (siRNA)
Duplexed RNA oligonucleotides for rat GATA-4
(Stealth RNAi ™) were synthesized by Invitrogen. H9c2
cells were transfected with 40 pmol of GATA-4-specific
siRNAs (siRNA-GATA-4) or scramble siRNA (siRNA-
control) using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s protocols that cells were trea-
ted with siRNA for 48 hr.
Cell contractility assay
In the study of cell contraction, H9c2 cells were measured
by the change in the planar surface area, as described pre-
viously [31]. H9c2 cells were cultured in 6-mm flat-bot-
tomed plates approximately 5x10
5 cells/ plate. Culture
plates were then mounted on the heated stage of an
inverted light microscope for the contractility assay.
Changes in the planar surface areas in response to treat-
ment were observed using a video camera, and images of
the cells were captured serially at 0, 20, 40, and 60 min.
Cells of the same group (n = 6-10) were collected at the
same time points. The perimeters of individual cells with
clearly-defined borders were outlined, and the planar sur-
face area was calculated as a percentage change. Control
groups were monitored in cultures with vehicle alone.
Statistical analysis
Data are expressed as the mean ± SEM for the number
(n) of animals in one group as indicated. Statistical ana-
lysis was carried out using one-way ANOVA analysis
and Newman-Keuls Post-hoc analysis. A P-value of 0.05
or less was considered significant.
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Effects of hyperglycemia on cardiac output, protein
expression level of TnI and nucleus GATA-4
phosphorylation in diabetic rats
STZ-diabetic rats exhibited a lower cardiac output
than the normal controls (23.6 ± 0.3 vs. 11.6 ± 0.4 ml/
min, P < 0.001, n =3 )( F i g u r e1 A ) .T h el e v e l so fTnI
protein expression and nucleus GATA-4 phosphoryla-
tion were significantly increased in the hearts of dia-
b e t i cr a t sa sc o m p a r e dw i t ht h en o r m a lc o n t r o l s
(Figure 1B, 1C). After treatment with insulin or phlor-
idzin for 7 days, in parallel to the reversion of blood
sugar, recovery of TnI p r o t e i ne x p r e s s i o no rn u c l e u s
GATA-4 phosphorylation was observed in the hearts
of STZ-diabetic rats (Figure 1B, 1C).
Characterization of superoxide generation in high-
glucose-treated neonatal rat cardiomyocytes and H9c2
cells
To understand the effect of a high-glucose environ-
ment on attenuating oxidative stress, we treated cells
with various concentrations of D-glucose (5.5, 10, 20
or 30 mM). The lucigenin assays showed that the gen-
eration of intracellular ROS in HG-treated neonatal rat
cardiomyocytes and H9c2 cells was enhanced as com-
pared with their control groups (Figure 2). DHE stain-
ing also indicated that a high glucose concentration
c a u s e da ni n c r e a s ei nt h es u p e r o x i d el e v e li nb o t hc u l -
tured neonatal rat cardiomyocytes (Figure 2A) and
H9c2 cells (Figure 2B).
Increase of TnI and phosphor-GATA-4 protein expression
in high glucose-treated neonatal rat cardiomyocytes and
H9c2 cells
The effects of hyperglycemia on the protein levels of
TnI and phospho-GATA-4 were further characterized in
cultured neonatal rat cardiomyocytes and H9c2 cells
exposed to various concentrations of glucose in vitro.
The protein levels of TnI and phospho-GATA-4 in
H9c2 cells were increased by high glucose concentra-
tions after 24 hrs of incubation (Figure 3A, 3B). How-
ever, the expressions were not changed in mannitol-
treated neonatal rat cardiomyocytes and H9c2 cells,
indicating that mediation of hyperosmolarity seems unli-
kely. Actually, the increase in TnI or phospho-GATA-4
protein expression caused by a high glucose concentra-
tion in H9c2 cells is similar to that observed in diabetic
hearts (Figure 1). This increase of TnI or phospho-
GATA-4 protein expression in neonatal rat cardiomyo-
cytes and H9c2 cells caused by a high glucose concen-
tration was markedly reversed by tiron treatment
(Figure 3). Thus, we continued our studies of H9c2 cells
to investigate the possible mechanisms of HG-induced
TnI and phosphor-GATA-4 protein expression in hyper-
glycemia-treated cells.
Effect of mitogen-activated protein kinase (MAPK) on the
phosphorylation of nucleus GATA-4 and expression of
cTnI in high glucose-treated H9c2 cells
The transcriptional activity of GATA-4 could be
enhanced via a p38 and MEK/ERK MAPK-dependent
pathway to phosphorylate GATA-4 activation domains
and GATA binding sites for the activation of target car-
diac promoters [15,16,32]. To identify the role of MEK/
ERK and the p38 MAPK-dependent pathway in GATA-
4 phosphorylation and cTnI expression, PD98059 (20
μmol/L) (MEK/ERK inhibitor) and SB203580 (25 μmol/
L) (p38 inhibitor) were used to treat H9c2 cells incu-
bated in a high-glucose medium. We observed that
PD98059 could reverse these actions (24%) but
SB203580 failed to do so (Figure 4A and 4B). Further-
more, we treated H9c2 cells with phenylephrine (PE) as
an activator of the MEK/ERK MAPK-dependent path-
way, and found that the cTnI protein level expression
was markedly increased in normal medium without
high-glucose treatment. However, this change was also
reversed by PD98059 (Figure 4C).
Silencing of GATA-4 could reverse the expression of cTnI
in high-glucose-treated H9c2 cells
We used siRNA specific for GATA-4 to silence the
expression of GATA-4 (Figure 5A) and verified the
GATA-4 induced cTnI generation in high-glucose-trea-
ted H9c2 cells. We found that the high-glucose-induced
increase in cTnI expression was markedly reduced when
GATA-4 was silenced (Figure 5B).
GSK3b regulates nuclear localization of GATA-4 in
neonatal rat cardiac myocytes and H9c2 cells
It has been established that GSK3b negatively regulates
the nuclear expression of GATA-4 [23]. In the present
study, GATA-4 was gradually increased in the nucleus by
high-glucose treatment in a time-dependent manner
(Figure 6A). Ser-9 phosphorylation of GSK3b has been
reported to reverse GSK3b-induced inhibition of GATA-
4 in cardiac myocytes [23]. Thus, we detected the level of
GSK3b phosphorylation. The HG-induced phosphoryla-
tion level of GSK3b was increased in a time-dependent
manner (Figure 6B). This change in GSK3b was corre-
lated with the HG-induced nuclear translocation of
GATA-4 (Figure 6A). Phosphorylation of GSK3b in H9c2
cells was significantly decreased by PD98059. Accumula-
tion of GATA-4 in the nucleus was observed after
GSK3b was inhibited by PD98059 (Figure 6B and 6D).
Similar result was observed in neonatal cardiac myocytes
(Figure 6C).
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The cell contraction assay was performed in the four
experimental groups as follows: (1) in regular medium
(control); (2) in high-glucose medium (HG); (3) incuba-
tion with siRNA of GATA-4 in high-glucose medium
(GATA-4 RNAi + HG); (4) incubation with scramble
RNA in high-glucose medium (Scramble + HG).
Changes in the planar surface areas of cells in response
to phenylephrine (PE) challenge at 0, 20, 40, and 60 min
were recorded (Figure 7A). Before the addition of PE,
the differences in the baseline planar areas of the four
groups were statistically insignificant. After PE chal-
lenge, the cell planar areas decreased gradually and dif-
fered from their original sizes after 60 min. However,
cells treated with a high glucose concentration lost con-
tractility after PE challenge as compared with the
Figure 1 Cardiac output and cardiac GATA-4 phosphorylation and troponin I expression in the heart. Comparison of streptozotocin-
induced diabetic rats (STZ) and normal (Wistar) rats. Each column shows the mean ± SEM (n = 6). ***P < 0.001 (A). STZ diabetic rats were
treated with insulin or phlorizin at a dose sufficient to correct the blood sugar level for 4 days. Then, rats were sacrificed and nuclear GATA-4
phosphorylation (B) and troponin I expression (C) were detected by Western blot analysis. The results are presented as the mean ± SEM (n =6
per group). *P < 0.05 and **P < 0.01 as compared with the STZ rats.
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siRNA-GATA-4 in high-glucose medium exhibited no
significant difference in cell contractility as compared
with the control group. Loss of contraction was
observed in the scramble RNA-treated cells under high-
glucose treatment in a way significantly different (P <
0.05) from that of the siRNA of GATA-4-treated cells
under high-glucose treatment (Figure 7B).
Discussion
In the present study, we confirmed that diabetic rats
exhibit a lower cardiac output than normal rats (Figure
1A). We also found that the expression of inhibitory
troponin (cTnI) was significantly increased in the heart
of diabetic rats (Figure 1C). Although diabetes-related
cTnI expression has not been discussed previously,
many studies have demonstrated that cTnI expression is
Figure 2 Effects of tiron on ROS generation in neonatal rat cardiomyocytes and H9c2 cells. DHE staining was used to visualize the
intracellular ROS and lucigenin assays were used to quantify the generation of superoxide in neonatal rat cardiomyocytes (A) and H9c2 cells (B).
*P < 0.05 and **P < 0.01 compared with the control;
#P < 0.05 and
##P < 0.01 compared with HG.
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[33-35] and drug-induced cardiac hypertrophy [36,37].
Similar to our previous report [38,39], correction of
h y p e r g l y c e m i ab yi n s u l i no rphlorizin reverses this
higher expression of cTnI in STZ rats (Figure 1C). The
role of hyperglycemia can thus be considered. In cul-
tured neonatal rat cardiomyocytes and H9c2 cells, a car-
diacmyocyte-like cell line, high-glucose treatment for 24
hr increased the expression of cTnI (Figure 3). The cell
contractility was also significantly decreased by a high
glucose concentration as compared with the control
group in the phenylephrine challenge test (Figure 7).
Both data collected from in vitro and in vivo experi-
ments supported the major role of hyperglycemia.
It has been documented that high glucose concentra-
tions may increase ROS production, causing diabetic
cardiomyopathy [40]. Antioxidants could reverse high-
glucose-induced cardiac injury [41-43]. In this study,
Figure 3 GATA-4 and cardiac troponin I expression in neonatal rat cardiomyocytes and H9c2 cells. Cell nuclear fractions were isolated for
Western blot analysis to detect the phosphorylation level of GATA-4 and troponin I in neonatal rat cardiomyocytes (A) and H9c2 cells (B). All
values are expressed as the mean ± SEM (n = 4). **P < 0.01 and *** P < 0.001 as compared with high glucose-treated H9c2 cells.
Ku et al. Cardiovascular Diabetology 2011, 10:57
http://www.cardiab.com/content/10/1/57
Page 8 of 15tiron at concentrations sufficient to scavenge ROS also
attenuated the expression of cTnI caused by high glu-
cose concentrations. A role of intracellular ROS in the
increased expression of cTnI can thus be considered in
cardiac cells.
GATA-4 is found in cardiac myocytes and regulates
many cardiac-specific gene expressions [44], such as atrial
natriuretic factor (ANF), beta-type natriuretic peptide
(BNP), myosin heavy chain (MHC), angiotensin II type IA
receptor and endothelin-1. In adults, over-expression of
GATA-4 could activate ventricular hypertrophic-related
genes [45,46]. We observed that expression of GATA-4 is
raised in STZ-diabetic rats (Figure 1B). It is of special
interest that the ratio of phosphorylated GATA-4 and
Figure 4 Effects of MAPK inhibitors on the level of p-GATA-4 and cardiac cTnI expression. H9c2 cells were incubated with SB203580 (25
mmol/L) or PD98059 (20 mmol/L) for 30 min before exposure to 30 mmol/L glucose. Then, nuclear fractions were isolated for Western blot
analysis of GATA-4 phosphorylation (A) and cardiac troponin I expression (B). In another group, H9c2 cells were treated with 1 mmol/L
phenylephrine (PE) in normal medium for 24 hr. Western blotting analysis was then used to estimate the effect of PD98059 on the expression of
troponin I induced by PE (C). The results are presented as the mean ± SEM (n = 3-5 per group). *P < 0.05, **P < 0.01 as compared with the high
glucose-treated group.
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Page 9 of 15Figure 5 Effects of GATA-4-specific RNAi on GATA-4 and cTnI expression in H9c2 cells. H9c2 cells were transfected with siRNA specific to
GATA-4 (RNAi) or scrambled RNA (Scr) for 24 hr and then exposed to 30 mmol/L glucose for another 24 hr. Whole cell lysates were isolated for
Western blot analysis of GATA-4 (A) and troponin I (B) protein expression. H9c2 cells cultured in regular medium were used as the control (Con).
The results are presented as the mean ± SEM (n = 3-5 per group). *P < 0.05, **P < 0.01 as compared with the high glucose-treated group.
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Page 10 of 15GATA-4 in the nucleus is changed with correction of the
blood sugar level (Figure 1B). Moreover, the high glucose-
induced increase in the expression of cTnI is reversed by
siRNA of GATA-4 (Figure 5) in a way similar to the
change in cell contractility (Figure 7). Thus, mediation of
GATA-4 in the high glucose-induced increase in expres-
sion of cTnI is reliable.
It has been well-established that hypertension and sti-
mulation with isoproterenol, phenylephrine, endothelin
or other hypertrophic signals can activate GATA-4
through the MEK/ERK pathway to promote GATA-4
serine105 p38 phosphorylation for higher binding of
GATA-4 on the specific promoter region to increase the
transcriptional activity [15,16]. In the present study,
PD98059 at a concentration (20 μmol/L) sufficient to
inhibit MEK/ERK blocked the high glucose-induced
GATA-4 serine105 phosphorylation and suppressed the
expression of cTnI (Figure 4). We further used pheny-
lephrine (10 μmol/L) to activate the MEK/ERK pathway
in cells cultured in normal medium. Phenylephrine act
as a-adrenergic receptor agonist that specifically activate
MAPK(Mitogen-activated protein kinase) pathway with-
out affect cAMP (cyclic adenosine monophosphate) acti-
vation that is induced by isoproterenol. The result
showed that activation of the MEK/ERK pathway with-
out high-glucose treatment could also increase the
$ %
&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Figure 6 Effect of MEK/ERK inhibitor on GSK3b phosphorylation and GATA-4 translocation in neonatal rat cardiacmyocytes and H9c2
cells. H9c2 cells were exposed to 30 mmol/L glucose for 24 hrs, and subsequently the nuclear fraction and cytosolic fraction were isolated for
Western blot analysis of GATA-4 expression and GSK3b phosphorylation (A and B). Changes in GATA-4 localization were also measured using a
fluorescent microscope. Counter staining of the cell nucleus was achieved using DAPI (4’, 6-diamidino-2-phenylindole) (A and D). H9c2 cells were
incubated with PD98059 (20 mmol/L) for 30 min and subsequently exposed to the same glucose concentration (30 mmol/L) for 24 hr. The
nuclear fractions were then isolated for Western blot analysis to measure phosphorylation of GSK3b (B). Result of western blot analysis in
neonatal rat cardiomyocytes treated with HG at various doses(C). The results are presented as the mean ± SEM (n = 3 per group). *P < 0.05 as
compared with the high glucose-treated group.
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Page 11 of 15phosphorylation of GATA-4 serine105, as we have shown
under high-glucose conditions previously. Furthermore,
the results showed that phenylephrine could increase the
expression of cTnI under normal conditions without a
high glucose concentration (Figure 4). Cells treated with
phenylephrine showed similar responses to high glucose
treated group on GATA-4 to increase cTnI expression
through MEK/ERK pathway can be considered.
Moreover, GATA-4-mediated transcription is mark-
edly attenuated by GSK3b.G S K 3 b negatively regulates
the nuclear expression of GATA-4 by stimulating
nuclear export. Inhibition of GSK3b by a-adrenergic sti-
mulation abrogates GSK3b-induced nuclear export of
GATA-4, causing nuclear accumulation of GATA-4
[23]. In the present study, we observed that a high glu-
cose concentration can increase the phosphorylation of
$
Figure 7 Effects of GATA-4 specific siRNA on phenylephrine (PE)-induced cell contraction in H9c2 cells. The high glucose-treated H9c2
cells were incubated with siRNA-GATA-4 (Si) or scrambled RNA as a control (Scramble) for 24 hr before PE challenge and then their planar
surface area was measured. The upper panel (A) shows a representative change of cells in each group. The lower panel (B) expresses the
differences between the four groups as the mean ± SEM (n = 6 per group). The high glucose-treated group differed markedly from the control
incubated in normal medium (***P < 0.001). The high glucose-treated GATA-4 RNAi group differed markedly from the scrambled RNA-treated
group treated with a high glucose concentration (
##P < 0.01,
###P < 0.001).
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Page 12 of 15GSK3b and GATA-4 accumulation in the nucleus. Also,
both actions were blocked by PD98059, showing media-
tion of the MEK/ERK pathway.
The sacromere is constructed from thick filament and
thin filament; the thick filament consists of myosin mole-
cules and the thin filament is composed of actin, tropo-
myosin, and troponin complex. Transcriptional
regulation of the MHC gene is complex and is initially
activated by the intricate genetic program of cardiac
development. However, GATA-4 depletion has been
identified to show no effect on the expression of MHC
[47]. In this study, we demonstrated that TnI is regulated
by GATA-4. This finding may suggest that GATA-4
plays a role in modulation of the thin filament. Further-
more, it has been documented that high glucose is predo-
minantly responsible for the decrease of IP3-induced Ca
2
+ transients noted in VSMCs from diabetic animals [48].
Our findings indicated that GATA-4 attenuated the
expression of TnI under hyperglycemic conditions. These
r e s u l t sm a yu s ea so n eo ft h ep o s s i b l em e c h a n i s m st o
explain why cardiac contractility is decreased in rats suf-
fering from hyperglycemia. However, the real mechanism
(s) shall be investigated in the future.
Conclusions
We have demonstrated that hyperglycemia-induced ROS
activate the MEK/ERK pathway to increase GATA-4
phosphorylation for higher transcription. In addition,
MEK/ERK activation causes GSK3b phosphorylation to
lower the export of GATA-4 and leads to further
GATA-4 accumulation in the nucleus. Thus, the expres-
sion of cTnI is raised (Figure 8). Taken together,
Figure 8 Possible mechanism of hyperglycemia in change of cardiac troponin I expression in type-1 diabetic rats. Hyperglycemia-
induced ROS activates the MEK/ERK pathway to increase GATA-4 phosphorylation and nuclear translocation. Also, MEK/ERK activation causes
GSK3b phosphorylation, lowering the export of GATA-4 and leading to GATA-4 preservation in the nucleus, which finally leads to an increase in
the expression level of cTnI.
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tant factors that lead to a reduction in cardiac contracti-
lity in diabetic cardiomyopathy.
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